Background: Vaccines are a key strategy to stop the COVID19 pandemic. The present study was conducted to assess the incidence of Adverse Drug Reactions to the Covishield vaccine among healthcare workers. Materials and Methods: A cross-sectional, observational, questionnaire-based study was carried out on healthcare workers of R.U.H.S. College of Medical Sciences, Jaipur, Rajasthan. The study tool consisted of a digital questionnaire. Results: The present study was carried out among 316 healthcare workers who received the first dose of the Covishield vaccine. 83 (26.26%) participants complained of side effects after receiving the first dose of the Covishield vaccine. Fatigue (64), fever (52), body ache (40), swelling at the vaccination site (35), headache (25), and pain in the limb (18) were the most prevalent symptoms. Most post-vaccination symptoms were found to be mild. 67 participants showed side effects of vaccination within 24 hours while 16 showed side effects after 24 hours. Conclusion: This study reflects that onefourth of participants complained of side effects after receiving the first dose of the Covishield vaccine. These side effects are not severe and should not be an obstacle to the successful control of the Covid-19 pandemic in India.

This case report is about a rural 39 years old female of Asian origin and laborer by profession who developed Toxic Epidermal Necrolysis (TEN) with lamotrigine. She was a known case of Bipolar Affective Disorder Type 1 with psychosis on treatment with quetiapine, duloxetine, escitalopram, and etizolam for the last one and a half years and had no history of adverse effects with those drugs. Recently Lamotrigine was added to her regimen at a dose of 50 mg/day. She developed Stevens-Johnson syndrome (SJ syndrome) within two weeks of adding lamotrigine which progressed to Toxic Epidermal Necrolysis (TEN), SCORTEN scores 3, in the next 3-4 days. The sequence of events, reports of laboratory investigations, and management of TEN have been elaborated in this case report. On the Naranjo scale of causality, the suspected adverse drug reaction was established as ‘probable’ because the suspected culprit drug discontinuation led to improvement in the patient’s condition but a rechallenge was not tried.

The first paper describing female patients with Turner syndrome (TS) was published in 1938 by Henry Turner[1]. It was later discovered that in 1930, Otto Ullrich had already reported a case report of a girl with suggestive symptoms of TS[2]. Therefore, the complete name is Ullrich-Turner syndrome.
Turner’s syndrome is a pathology found only in females, characterized by the partial or total absence of a second sex chromosome which leads to a wide range of physical findings that often includes congenital lymphedema, short stature, and gonadal dysgenesis[1]. The physical symptoms depend on the karyotype, as only 50% of Turner patients are 45,X the others displaying mosaics or abnormalities in the second sex chromosome. [...]